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COMPARATIVE EVALUATION OF TBROMBO?IYTIC PROPW- 
TIES OF A NOVEL PLASMINOGEN ACTIVATOR IN DOGS 
DIFFERENTIALEFFECTSOFHEPARINAND 
HIRUDlNONTHROMBOLYSISIN V..RO 
Gisbert Sponer, Klaus Strein, 
&ology, Boehringer Mannheim G&H, Ethan J. Haskel, Paul R. Eisenberg, Burton B. Sobel, Dana R. 
Abendschein, Washington University, St. Louis, MO USA 
The novel plasminogen activator BlY 06.022 con- 
sists of the kringle 2 and protease domains of 
t-PA without oligosaccharide side-chains. Throm- 
bolytic properties and systemic effects of 
BM 06.022 were comparatively investigated in a 
canine stenotic model of left circumflex corona- 
ry artery thrombosis induced by electrical sti- 
mulation. One h after thrombus formation, 140 
kU/kg BM 06.022, 1 mg/kg alteplase, or 0.4 mg/kg 
anistreplase were i.v. injected; 21 000 U/kg 
streptokinase or 40 000 U/ kg urokinase were 
i.v. infused. Reperfusion rate (RR), time to 
reperfusion (TR), residual fibrinogen (RF), and 
90-min simplate bleeding time (BT) were assessed 
in 6 dogs/agent. Vehicle-injected dogs did not 
reperfuse. 
BM Alte- Aldstm- strepto- uro- 
06.022 plase plase kinase 
RR 4/6 2/6 5/G 3/c 3/6 
‘IRWN 18s 36 58,+27* 67221* 84_+30* 
WV 969 9324 w* 10124 2*11* 
BT(min) 2.592 2.w.2 1424* 1w3* 6,3*2* 
ispI: *vs 06.022 pco. 05 
We conclude that intravenous bolus injection of 
BM 06.022 achieved rapidly a high reperfusion 
rate without inducing significant systemic ef- 
fects. Therefore, BM 06.022 appears to combine 
selectively the advantages of the reference 
thrombolytic agents. 
Concomittant administration of inhibitors of thrombin and tissue-type 
plasminogen activator (t-PA) appears to potentiate thrombolysis. 
However, mechanisms responsible have not been completely defined. 
To characterize the effects of thrombin inhibition on thrombolysis we 
compared the extent of lysis over 60 min of ‘2%fibrinogen-labeled 
human whole blood clots in nonanticoagulated whole blood induced by 
addition of either 1.5 @nl of t-PA alone or t-PA with increasing 
concentrations of heparin or recombinant hirudin, a direct-acting 
antithrombin. Results follow: 
Heparin, U/ml, (n) .1(4) .3(3) .X4) 
PIT (times control) 
.;y 1.0(4) 
2.4 
% A in lysis J(46220) A(3&27) (0$3, f(7;:13) t(4>2&18) 
vs t-PA alone 
Hsdin, pg/ml, (n) iS14) 1.0(4) 2.5(4) S-O(4) 1@.0(4) 
%I A in lysis t(32;l g)* t(2;:24) t&&)!$ $&3 1) t( l>jj7_+48) 
*p=O.O3 vs heparin 0.1 U/ml, §p=O.OS vs heparin 0.2 U/ml 
Similar results were obtained with whole blood clots incubated with t- 
PA in recalcified platelet-poor plasma. However, clot lysis induced 
with t-PA was not increased even with high concentrations of heparin 
or hirudin when clots were incubated in secalcified tibrinogenemic 
plasma. Thus, unlike heparin, specific inhibition of thrombin by 
hirudin increases clot lysis induced by t-PA in nonanticoagulated blood 
at all concentrations. Inhibition of thrombin appears to potentiate clot 
lysis by preventing the formation of fibrin, which may otherwise 
compete with clot-associated fibrin for binding of t-PA. 
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ACETYLCHOLIUE AND BRADYKIRIW RELEASE BWDOTHELIW 
DEPEQDERT ANTITHROKBOTIC SUBSTANCES 
Jules Y.T. Lam, Johanne Baribeau , David Waters, 
Montreal Heart Institute, Montreal, Canada 
By releasing metabolically active 8ubstance8, the endo- 
thelium modulates vasomotor responsiveness. These sub- 
stances (EDRF, PCI2, 1%HODE or others) may also 
affect platelet function, but it is not clear whether 
they contribute to vessel wall thromboresistance. The 
pO88ible antithrombotic properties of endothelial sub- 
stances released by stimulation 
(Ach) or bradykinin (BK) on quantitative 
with ac:&r_l;;l:;z 
labelled platelet deposition (PD. ~106) onto aortic 
media exposed to flowing blood in an ex vivo superfu- 
sion flow chamber were studied. Non-anticoagulated 
arterial blood from a normal pig was drawn into 1 nrm 
diameter chambers at 20 ml/min for 3 min at 37OC by a 
peristaltic pump. Serial perfusion over aortic endathe- 
lium followed by aortic media was performed. The efflu- 
ent from an Ach <lo-5M) or BK (lo-SW stimulated 
aortic endothelium induced a decrease in PD on the 
aortic mdia downstream, (11.6k1.7, n=6 or 12.3k1.9, 
n=8) relative to non-stimulated endothelium, super- 
fusing Ach or BK stimulated media only (41.2kl. 7 or 25- 
.8&1.4, p<O.OOOl). However, PD on the aokstrean-;eaIa 
was unchanged when Ach (10-6~) or saline perfused a 
proximal media without endothelium (24.3k3.3, n=14 VI 
28.7k3.9, n-15, p=tW. Pretreatment of the endothelial 
tissue with aspirin (lo-3kl) did not significantly 
alter the endothelial effects. 
ThUP, antithrombotic substances can be released by 
Stimlated vessel wall with, but not without, intact 
endothelium. These substances are resistant to aspirin 
inhibition and may influence platelet-vessel wall 
interaction and thrombogenicity. 
ACI'IVATIONOFENDOTHELINDURINGARTERIAL 
THROMF3osIsANDTHRoMBoLYsIs. 
a, Jozef S. Mruk, Mark WI. Webster, John C. Burnett 
Jr., James H. Chesebro. Mayo Clinic, Rochester, Minnesota, USA. 
Endothelin (ET) is an endothelial-derived peptide which 
possesses potent vasoconsaictor properties in vitro and in vivo, and 
has been implicated as a mediator of vasospasm Recent studies have 
demonstrated that thrombin and endothelial cell injury may stimulate 
endothelin release. The cmnt study was designed to test the 
hypothesis that circulating ET concentrations are increased following 
thrombus formation and reperfusion with recombinant human tissue 
plasmin activator (TPA) in anesthetized pigs (n=8). Deep arterial 
injury with formation of occlusive thrombus were fanmd in the left 
c?tld artery by balloon angioplasty followed by endarterectomy 
usmg a Simpson’s atherectomy catheter. After a 30 min. equilibration 
period TPA was initiated( 0.3 mg/kg iv bolus followed by infusion at 
3 mg/kg/hr). Blood samples were collected from the left jugular vein 
and left femoral artery at baseline, 30 min after thrombus formation 
(THR), at the initiati& (TPA-0) and 90 min into the TPA infusion 
(‘WA-90). Plasma ET was determined by a newlv develoned 
